Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.05
+0.09 (0.64%)
Nov 4, 2024, 4:00 PM EST - Market closed

Takeda Pharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Nov '24 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 2019 - 2015
Market Capitalization
44,25543,39950,86944,66256,32947,893
Upgrade
Market Cap Growth
-6.03%-14.68%13.90%-20.71%17.62%-24.50%
Upgrade
Enterprise Value
75,32075,91881,75574,56398,21894,787
Upgrade
Last Close Price
14.0513.8915.9413.3616.3813.12
Upgrade
PE Ratio
21.8623.0510.4911.127.5849.97
Upgrade
PS Ratio
1.431.541.681.521.951.57
Upgrade
PB Ratio
0.940.901.060.951.201.09
Upgrade
P/FCF Ratio
9.9312.148.085.426.929.50
Upgrade
P/OCF Ratio
7.249.166.924.836.167.69
Upgrade
EV/Sales Ratio
2.372.692.702.543.403.10
Upgrade
EV/EBITDA Ratio
8.1210.098.987.6511.0411.59
Upgrade
EV/EBIT Ratio
16.5123.2817.5415.0925.6234.38
Upgrade
EV/FCF Ratio
16.9121.2312.999.0612.0718.79
Upgrade
Debt / Equity Ratio
0.810.750.770.850.981.16
Upgrade
Debt / EBITDA Ratio
4.074.603.864.075.166.21
Upgrade
Debt / FCF Ratio
8.2810.105.814.815.6410.07
Upgrade
Asset Turnover
0.310.290.300.270.250.25
Upgrade
Inventory Turnover
1.311.301.361.401.341.33
Upgrade
Quick Ratio
0.660.500.490.731.000.65
Upgrade
Current Ratio
1.281.110.971.211.531.13
Upgrade
Return on Equity (ROE)
4.15%2.12%5.27%4.24%7.60%0.89%
Upgrade
Return on Assets (ROA)
2.77%2.12%2.85%2.87%2.06%1.39%
Upgrade
Return on Capital (ROIC)
3.29%2.57%3.57%3.62%2.59%1.74%
Upgrade
Earnings Yield
4.57%2.19%4.69%4.24%6.04%0.86%
Upgrade
FCF Yield
10.07%8.24%12.37%18.44%14.44%10.53%
Upgrade
Dividend Yield
4.45%8.95%8.49%11.10%9.93%12.75%
Upgrade
Payout Ratio
49.21%199.34%88.14%123.30%75.36%638.73%
Upgrade
Buyback Yield / Dilution
-1.07%-0.67%0.46%-0.23%-0.47%-61.98%
Upgrade
Total Shareholder Return
3.38%8.28%8.96%10.87%9.47%-49.23%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.